19 Jan 2023
Although we are not issuing a formal press release, we wanted to let you know that NICE has today (19 January 2023) published final draft guidance which now recommends ataluren (also called Translarna and made by PCT Therapeutics) for treating Duchenne muscular dystrophy (DMD) caused by a nonsense mutation.
Today’s decision follows NICE’s commitment to re-evaluate ataluren and decide whether it should be available routinely in England and Wales following a 6-year period during which it was available under a managed access agreement (MAA). This agreement, which ends on 20 January, meant that people could have the treatment while more data to resolve issues about its effectiveness was collected. Around 60 children have been able to have ataluren under this arrangement.
The data collected as part of the MAA, together with new real-world evidence (evidence collected outside clinical trials) on ataluren and feedback from clinicians and patients has been reviewed for this draft guidance.
It suggests that ataluren is likely to slow down disease progression and delay the time at which the ability to walk is lost. Evidence for improvements in later stages of the disease and improved survival with ataluren is limited and highly uncertain. However, the committee agreed that ataluren may also improve outcomes, such as preventing scoliosis and maintaining upper body strength, once the ability to walk has been lost.
Taking all the evidence into account, together with an improved commercial arrangement agreed with the company after the second committee meeting, the cost-effectiveness estimates for ataluren are within the range that NICE usually considers acceptable for highly specialised technologies.
One of a group of muscular dystrophies, DMD is a severe, progressive muscle-wasting genetic condition caused by the lack of a protein called dystrophin. It leads to gradual decline in muscle function with children often needing to use a wheelchair by early adolescence and eventually requiring artificial ventilation to breathe.
There are between 60 and 70 children, mostly boys, born with DMD in England each year and in around 6 – 9 children (13%) it is caused by a ‘nonsense mutation’.
Costing around £220,000 per patient per year at its list price, ataluren is the first licensed treatment for DMD that addresses the loss of the protein dystrophin. It works by allowing the body to read over the mutation in the DNA and continue to produce the protein.
NHS England has confirmed that it will routinely commission ataluren based on the recommendations in the final draft guidance immediately, ensuring continuity of access to the treatment for all current and new patients.
References
Dosage is weight based and this cost is based on a median weight. Costs would be higher when considering the average weight. There is a confidential discount to the price of ataluren agreed with NHS England.
Philip Ranson
philip.ranson@nice.org.uk
NICE’s core purpose is to help practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
We do this by:
To find out more about what we do, visit our website: www.nice.org.uk and follow us on social media.